704 related articles for article (PubMed ID: 31560051)
41. Clostridioides difficile infection: Incidence and risk factors in a tertiary care facility in Riyadh, Saudi Arabia.
Alzouby S; Baig K; Alrabiah F; Shibl A; Al-Nakhli D; Senok AC
J Infect Public Health; 2020 Jul; 13(7):1012-1017. PubMed ID: 31831398
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
[TBL] [Abstract][Full Text] [Related]
43. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
[TBL] [Abstract][Full Text] [Related]
44. Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.
Darkoh C; Keita K; Odo C; Oyaro M; Brown EL; Arias CA; Hanson BM; DuPont HL
Clin Infect Dis; 2022 Jan; 74(1):120-126. PubMed ID: 35016207
[TBL] [Abstract][Full Text] [Related]
45. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China.
Cui Y; Dong D; Zhang L; Wang D; Jiang C; Ni Q; Wang C; Mao E; Peng Y
BMC Infect Dis; 2019 Nov; 19(1):961. PubMed ID: 31711425
[TBL] [Abstract][Full Text] [Related]
46. Implementation of the Targeted Assessment for Prevention Strategy in a healthcare system to reduce
White KA; Soe MM; Osborn A; Walling C; Fike LV; Gould CV; Kuhar DT; Edwards JR; Cochran RL
Infect Control Hosp Epidemiol; 2020 Mar; 41(3):295-301. PubMed ID: 31928537
[TBL] [Abstract][Full Text] [Related]
47. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
48. Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients.
Haeusler GM; Lehrnbecher T; Agyeman PKA; Loves R; Castagnola E; Groll AH; van de Wetering M; Aftandilian CC; Phillips B; Chirra KM; Schneider C; Dupuis LL; Sung L
Eur J Cancer; 2022 Aug; 171():1-9. PubMed ID: 35696884
[TBL] [Abstract][Full Text] [Related]
49. Potential impact of removing metronidazole from treatment armamentarium of mild acute
Zilberman-Itskovich S; Youngster I; Lazarovitch T; Bondarenco M; Toledano L; Kachlon Y; Mengesha B; Strul N; Zaidenstein R; Marchaim D
Future Microbiol; 2019 Nov; 14():1489-1495. PubMed ID: 31913060
[No Abstract] [Full Text] [Related]
50.
MacKenzie EL; Murillo C; Bartlett AH; Marrs R; Landon EM; Ridgway JP
Infect Control Hosp Epidemiol; 2023 Nov; 44(11):1782-1787. PubMed ID: 36658099
[TBL] [Abstract][Full Text] [Related]
51. A Multicenter Evaluation of Probiotic Use for the Primary Prevention of Clostridioides difficile Infection.
Heil EL; Harris AD; Brown C; Seung H; Thom KA; von Rosenvinge E; Sorongon S; Pineles L; Goodman KE; Leekha S
Clin Infect Dis; 2021 Oct; 73(8):1330-1337. PubMed ID: 33972996
[TBL] [Abstract][Full Text] [Related]
52. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.
Tanaka Y; Tashiro S; Ikegami S; Enoki Y; Taguchi K; Matsumoto K
Anaerobe; 2023 Dec; 84():102789. PubMed ID: 37879532
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological Management of Pediatric Clostridioides difficile Infection: Clarifying the Controversies.
DeVine MN; MacBrayne CE; Child J; Blackmer AB
J Pediatr Health Care; 2022; 36(2):181-192. PubMed ID: 34412953
[TBL] [Abstract][Full Text] [Related]
54. Cost and length of hospital stay for healthcare facilityonset Clostridioides Difficile infection in pediatric wards: a prospective cohort analysis.
Demir SÖ; Kepenekli E; Akkoç G; Yakut N; Soysal A
Turk J Pediatr; 2021; 63(6):1004-1011. PubMed ID: 35023650
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
Carignan A; Poulin S; Martin P; Labbé AC; Valiquette L; Al-Bachari H; Montpetit LP; Pépin J
Am J Gastroenterol; 2016 Dec; 111(12):1834-1840. PubMed ID: 27619835
[TBL] [Abstract][Full Text] [Related]
56. Evidence of within-facility patient-patient
Justice S; Sewell DK; Li H; Miller AC; Polgreen PM
Epidemiol Infect; 2022 Dec; 151():e4. PubMed ID: 36502810
[TBL] [Abstract][Full Text] [Related]
57. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
58. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
60. Hospital-associated Clostridium difficile infection: is it necessary to track community-onset disease?
Dubberke ER; McMullen KM; Mayfield JL; Reske KA; Georgantopoulos P; Warren DK; Fraser VJ
Infect Control Hosp Epidemiol; 2009 Apr; 30(4):332-7. PubMed ID: 19239377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
